Amoxicillin-sulbactam:: A clinical and therapeutic review

被引:7
作者
Acuña, C [1 ]
Rabasseda, X [1 ]
机构
[1] Prous Sci, Dept Med Informat, Barcelona 08080, Spain
来源
DRUGS OF TODAY | 2001年 / 37卷 / 03期
关键词
D O I
10.1358/dot.2001.37.3.614856
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Combinations of beta -lactamase inhibitors with penicillins, especially aminopenicillins, have broad-spectrum antibacterial activity against most of the common pathogens of the respiratory and urinary tracts. This means that they are an ideal treatment for infections such as otitis media, sinusitis, special cases of pharyngeal tonsillitis (recurring forms, indirect pathogenic action, or after the failure of amoxicillin monotherapy), acute exacerbations of chronic bronchitis, cystitis, urethritis, etc. The amoxicillin-sulbactam combination is active against both beta -lactamase producer and nonproducer strains, and is effective against Gram-positive cocci (Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus of nonhospital origin), Gram-negative cocci (Neisseria gonorrhoeae, Moraxella catarrhalis and others), Gram-negative bacilli (nonhospital strains of Haemophilus influenzae, Escherichia coli and Klebsiella pneumoniae and others) and anaerobes. Its antimicrobial activity means that it is indicated in the treatment of respiratory, ear, nose and throat, urinary, dermatological and gynecological infections caused by susceptible germs, as well as in a variety of surgical situations (both as a treatment and as prophylaxis). it is absorbed very well orally, and its pharmacokinetic profile is very favorable, with very good tissue penetration. It is reasonably well tolerated: in a variable percentage of cases it may cause modification of intestinal transit and/or fecal consistency, which usually abates spontaneously. The new formulation for administration at intervals of 12 h is easier to use, is better tolerated and favors completion of therapy. In summary, the amoxicillin-sulbactam combination is effective and well tolerated in most infections of nonhospital origin in adults and children. (C) 2001 Prous Science. All rights reserved.
引用
收藏
页码:193 / 210
页数:18
相关论文
共 52 条
[1]  
ALONSO S, 1990, GINECOL REPROD, V2, P27
[2]  
Arenoso Hector Julio, 1995, Prensa Medica Argentina, V82, P471
[3]  
ARENOSO HJ, 1993, 6 EUR C CLIN MICR IN
[4]   Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-β-lactamase inhibitor combination, against Escherichia coli [J].
Bantar, C ;
Nicola, F ;
Arenoso, HJ ;
Galas, M ;
Soria, L ;
Dana, D ;
Rossi, A ;
Bianchini, H ;
Jasovich, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1503-1504
[5]   A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections [J].
Bantar, C ;
Nicola, F ;
Canigia, LF ;
Arenoso, HJ ;
Soutric, J ;
Montoto, M ;
Blanco, M ;
Smayevsky, J ;
Jasovich, A .
JOURNAL OF CHEMOTHERAPY, 2000, 12 (03) :223-227
[6]  
BOGADO H, 1992, PRENSA MED ARGENT, V79, P21
[7]  
CAHN P, 1990, PRENSA MED ARGENT, V77, P24
[8]  
CALAFELL EO, 1990, PRENSA MED ARGENT, V77, P15
[9]  
CASELLAS JM, 1993, REV ESP QUIM, V6, P289
[10]  
CASELLAS JM, 1977, 7 C LAT INF PED CAR